Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” The ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...